Arteriovenous Malformations Indication Strategy Report 2026: Evidence, Targets, Competition and Market Outlook

Published August 24, 2026 · Evidence accessed through Patsnap Life Sciences MCP servers.

This report evaluates one indication only: Arteriovenous Malformations. It connects disease context, epidemiology, target mechanism, clinical competition, transactions, unmet need and market attractiveness for portfolio and partnering decisions.

Executive assessment

Arteriovenous Malformations receives a directional strategic score of 59/100, combining unmet need (76/100), competitive intensity (96/100, where higher means more competition) and market attractiveness (80/100). The score is a transparent prioritization aid, not a revenue forecast, clinical recommendation or investment conclusion.

Disease background and strategic definition

Abnormal formation of blood vessels that shunt arterial blood directly into veins without passing through the CAPILLARIES. They usually are crooked, dilated, and with thick vessel walls. A common type is the congenital arteriovenous fistula. The lack of blood flow and oxygen in the capillaries can lead to tissue damage in the affected areas.

The reproducible entity is Patsnap disease ID 9272025ff3bf420cb743a766fe76de69 with MeSH identifier D001165. Stable identifiers are important because rare and precision-defined diseases often carry historical labels, gene-defined subtypes and overlapping syndromic names.

A credible target product profile should define phenotype, age, severity, diagnostic confirmation, prior therapy, treatment setting, acceptable safety and endpoint. A broad label may inflate theoretical market size while weakening biological signal, trial interpretability and recruitment feasibility. The first population should be narrow enough for coherent biology but large enough for execution.

The care pathway should be mapped from symptom recognition through referral, diagnostic testing, treatment initiation and longitudinal monitoring. Diagnostic delay, limited specialist centers and fragmented testing can constrain both trial enrollment and commercial access. These bottlenecks deserve explicit operational assumptions.

Epidemiology and disease burden

Epidemiology evidence 1: Heart Disease and Stroke Statistics—2021 Update

• Costs of AF have been estimated for many other countries. Investigators estimated that the 3-year societal costs of AF were ≈€20 403 to €26 544 per person and €219 to 295 million for Denmark as a whole.263 Global Burden of AF (See Charts 17-8 and 17-9) • The vast majority of research studies on the epide- miology of AF have been conducted in Europe and North America. Investigators from the GBD proj- ect noted that the global prevalence, incidence, mortality, and DALYs associated with AF increased from 1990 to 2010.264 • The GBD 2019 Study used statistical models and data on incidence, prevalence, case fatality, excess mortality, and cause-specific mortality to estimate disease burden for 369 diseases and injuries in 204 countries and territories.265 — Total number of global deaths attributable to AF/atrial flutter was ≈300 000 in 2019 (200 000 females and 100 000 males). — Globally, 59.7 million individuals had prevalent AF/atrial flutter in 2019 (29.4 million females and 30.3 million males). — Age-standardized mortality attributable to AF is highest in parts of Western Europe, Central Asia, and Australasia (Chart 17-8). — Age-standardized prevalence of AF is highest in Central and Eastern Europe, Australasia, and parts of North America (Chart 17-9). • Investigators conducted a prospective registry of >15 000 patients with AF presenting to EDs in 47 countries. They observed substantial regional variability in annual AF mortality: South America (17%) and Africa (20%) had double the mor- tality rate of North America, Western Europe, and Australia (10%; P<0.001). HF deaths (

Review the epidemiology source

Epidemiology evidence 2: Heart Disease and Stroke Statistics—2022 Update Heart Disease and Stroke Statistics—2022 Update: A Report From the American Heart Association

– PAD age-standardized prevalence was highest in high-income North America and Western Europe (Chart 25-5). Mortality • In the GBD 2020 study the age-standardized mor­ tality estimated for PAD was 0.93 (95% UI, 0.80– 1.00) per 100 000 individuals (Table 25-2).86 – PAD age-standardized mortality was highest in Central and Eastern Europe in 2020 (Chart 25-6). Aortic Diseases ICD-9 440, 441, 444, and 447; ICD-10 I70, I71, I74, I77, and I79. Aortic Aneurysm and Acute Aortic Syndromes ICD-9 441; ICD-10 I71. Prevalence • Estimating the prevalence of TAA is challenging because of the relatively few studies in which screen­ ing has been performed in the general population. – The prevalence of TAA >5 cm incidentally identi­ fied by community-based screening chest CT was estimated to be between 0.16% and 0.34% from studies performed between 1995 and 2003 in Japan and Germany.87,88 • AAA is more common in males than females, and its prevalence increases with age.89–92 – AAA is ≈4 times more common in males than females on the basis of data from an ultrasound- based screening study of 125 722 veterans 50 to 79 years of age conducted between 1992 and 1997.93,94 ▪ In males, the prevalence of AAAs 2.9 to 4.9 cm in diameter ranged from 1.3% to 12.5% in individuals 45 to 54 and 75 to 84 years of age, respectively. In females, the prevalence of AAAs 2.9 to 4.9 cm in diameter ranged from 0% in the youngest to 5.2% in the oldest age groups.95 ▪ Approximately 1% of males between 55 and 64 years of age have an AAA ≥4.0 cm, and every decade thereafter, the prevalence increases by 2% to 4%.96,97 I

Review the epidemiology source

Epidemiology evidence 3: Epidemiology and burden of alopecia areata in Taiwan: a systematic review

Although the modelling study by Jeon et al. (45) reported that the prevalence estimates tend to be higher in Asian regions, the estimated annual incidence rate and prevalence of AA in Taiwan reported in the latest study (estimated by total population in each year in Taiwan during 2017–2020) were 0.011 and 0.015%, respectively (10), which are lower than data reported in other countries. For instance, the estimated global incidence of AA varies between 0.1 and 3.8%, and the prevalence of AA is 0.1% (9, 45–47). In other Asian countries, the incidence rate in South Korea was 0.2%; and the prevalence ranged from 0.16 to 0.19% in Japan and 0.37% in South Korea (46, 48). A UK study showed a threefold higher AA incidence in people of Asian origin compared to those of white ethnicity (8). The geographic region, social factors, lifestyle and could cause differences in prevalence and incidence rate of AA (45). In addition to these factors, the lower incidence and prevalence of AA in Taiwan might be due to stricter case definition used in the study by Tsai et al. (i.e., ≥3 claims with AA diagnosis by dermatologists or rheumatologists) compared to other studies that used a one-time diagnosis as the inclusion TABLE 2 Summary of AA cohorts identified in the publications. TABLE 2 (Continued) I, estimated incidence per 1,000; ICD-9-CM, International Classification of Disease – 9th version- clinical modification; ICD-10-CM, International Classification of Disease – 10th version- clinical modification; Mn, million; NHIRD, National Health Insurance Research Database; P, estimated prevalence pe

Review the epidemiology source

Translate epidemiology into an addressable-patient funnel: total affected population → diagnosed patients → clinically eligible segment → treated patients → realistically accessible patients. Incidence, point prevalence and lifetime prevalence cannot be substituted for one another, and incompatible case definitions should not be pooled.

For Arteriovenous Malformations, quantify diagnostic yield, age and severity distribution, referral-center concentration, treatment penetration, survival and progression. Use conservative, base and upside ranges. Each parameter should have a source, access date and explanation of how it maps to the intended clinical population.

Population concentration can materially change strategy. A small but well-defined group managed in a limited number of centers may be operationally attractive, while a larger but poorly diagnosed population may require extensive testing and education. Epidemiology must therefore connect to the real patient journey.

Unmet need and patient-value thesis

Unmet need should identify a specific failure: irreversible progression, incomplete control, treatment-limiting toxicity, weak durability, burdensome administration, delayed diagnosis or lack of options for a biomarker-defined subgroup. Disease severity alone does not prove that a new program can demonstrate clinically meaningful benefit.

A strong Arteriovenous Malformations thesis connects mechanism to a prospectively defined responder population and an endpoint understood by regulators, clinicians, patients and payers. It tests whether benefit can be measured within a feasible time horizon and whether natural-history variability can be controlled. Functional measures, patient-reported outcomes and resource use may complement biomarkers.

Development should proceed through evidence gates. Establish phenotype and natural history, demonstrate target engagement, observe a pharmacodynamic response, show an interpretable clinical signal and only then scale toward registrational development. Pre-agreed stop criteria protect capital and improve learning from negative results.

Target mechanism anchor: RPE65

Critical isomerohydrolase in the retinoid cycle involved in regeneration of 11-cis-retinal, the chromophore of rod and cone opsins. Catalyzes the cleavage and isomerization of all-trans-retinyl fatty acid esters to 11-cis-retinol which is further oxidized by 11-cis retinol dehydrogenase to 11-cis-retinal for use as visual chromophore (PubMed:16116091). Essential for the production of 11-cis retinal for both rod and cone photoreceptors (PubMed:17848510). Also capable of catalyzing the isomerization of lutein to meso-zeaxanthin an eye-specific carotenoid (PubMed:28874556). The soluble form binds vitamin A (all-trans-retinol), making it available for LRAT processing to all-trans-retinyl ester. The membrane form, palmitoylated by LRAT, binds all-trans-retinyl esters, making them available for IMH (isomerohydrolase) processing to all-cis-retinol. The soluble form is regenerated by transferring its palmitoyl groups onto 11-cis-retinol, a reaction catalyzed by LRAT (By similarity).

The mechanism anchor is RPE65. It is a pathway hypothesis, not a claim that every Arteriovenous Malformations patient is target-dependent. Translational work should establish tissue expression, human genetic or biomarker support, pharmacologic tractability, target engagement, downstream modulation and a therapeutic window.

Critical experiments include orthogonal engagement assays, disease-relevant dose–response studies, biomarker qualification, compensatory-pathway analysis and explicit on-target and off-target safety testing. Human evidence should carry greater weight than model-only observations. Related clinical failures should be examined for exposure, population and endpoint lessons.

A go decision requires a complete chain: relevant target biology, achievable modulation at tolerated exposure, measurable pharmacodynamic change and a plausible bridge to clinical benefit. Missing links should trigger targeted experiments rather than narrative confidence.

Clinical development and competitive landscape

The focused query returned 651 registered studies. Recent sampled records include:

• ChiCTR2600130420 — A prospective multicenter cohort study of dural arteriovenous fistulas based on a standardized diagnosis and treatment system; Not yet recruiting; Not Applicable; sponsor Shanghai Huashan Hospital; enrollment 316.
• NCT07766525 — Complementary Music Therapy for Pain During Percutaneous Transluminal Angioplasty.; Completed; Not Applicable; sponsor Chang Gung Memorial Hospital; enrollment 114.
• NCT07754357 — Ultrasound-Guided T2 Erector Spinae Plane Block Versus Intercostobrachial Block in AV Fistula Surgery. (ICBN/ESP); Enrolling by invitation; Not Applicable; sponsor Aswan University; enrollment 110.

Trial count is not product count. Observational studies, natural-history cohorts and multiple studies from one asset can inflate activity. Normalize every record by phase, modality, mechanism, sponsor, recruitment status, geography, endpoint and exact disease subtype.

Competitive strategy should compare against the likely future standard at launch. Whitespace can arise from earlier treatment, genotype selection, improved durability, lower monitoring, safer chronic use, simpler administration or a rational combination. The differentiation claim must be visible in protocol design, not deferred to post hoc interpretation.

Recruitment risk is a core strategic variable. Site density, diagnostic testing, travel burden, competing protocols and screen-failure rates should inform country and center selection. Natural-history work can reduce uncertainty but cannot replace a controlled efficacy strategy when outcomes are variable.

Transaction activity and partnering attractiveness

No directly matched 2023–2026 transaction was returned. This may reflect limited partnering, broader transaction labels or asset-level indexing. Add target- and asset-based comparable searches before valuation.

Headline transaction value is rarely directly comparable. Separate upfront payments, milestones, royalties, options, bundled programs, platform rights and geographic scope. A useful comparable set matches indication, target, modality, stage and territory, then explains remaining differences.

Partner readiness requires a concise evidence room: disease segmentation, target-validation chain, competitive map, clinical plan, intellectual property, chemistry or manufacturability evidence and a transparent risk-adjusted value model. Outreach is most effective around a credible catalyst that retires material risk.

Low direct deal activity can represent whitespace, but it can also signal difficult science or economics. Broader therapeutic-area transactions should be used only when their relevance is explicit. Avoid assuming that all rare-disease transactions share the same valuation logic.

Market attractiveness and access

Market attractiveness depends on diagnosis infrastructure, specialist concentration, treatment duration, administration setting, payer controls, alternatives, monitoring burden and geographic reimbursement. Patient count is only one driver. Reliable identification and a meaningful effect may outweigh a small population; fragmented diagnosis can undermine a larger one.

The commercial model should use scenario ranges for diagnosed prevalence, eligible share, launch timing, competitive entries, net price, persistence and penetration. Every assumption should be traceable. Refresh the model when new epidemiology, trial or deal evidence becomes available.

Payer research should begin before pivotal design so comparator, endpoint and follow-up support reimbursement as well as approval. Evidence may need quality of life, caregiver burden, hospital use, diagnostic costs or productivity outcomes. The value proposition should connect clinical effect to stakeholder-relevant outcomes.

Risks and decision gates

• Disease-definition risk: confirm a consistently diagnosed and recruitable population.
• Biology risk: demonstrate RPE65 relevance in the selected phenotype.
• Translation risk: connect engagement to a biomarker and meaningful endpoint.
• Competition risk: refresh the landscape before every investment gate.
• Operational risk: validate sites, testing and screen-failure assumptions.
• Commercial risk: test pricing, access and adoption with clinicians and payers.
• Data risk: treat zero-result searches as prompts for broader queries, not proof of absence.

Recommended gates are population confirmation, human mechanism validation, differentiated target product profile, early proof of mechanism and scale-up only after biological, clinical, operational and commercial signals converge.

Strategic recommendation

Arteriovenous Malformations merits continued milestone-based evaluation. The opportunity is strongest if a phenotype or biomarker identifies patients with coherent biology, if RPE65 modulation is measurable and if the proposed benefit remains differentiated against future care. Current evidence supports targeted diligence rather than unconditional investment.

The near-term business-development objective is a partner-ready thesis explaining the patient segment, mechanism, competitive whitespace, development path and value-inflection milestones. The scorecard offers a common comparison language while preserving evidence gaps and uncertainty.

Methodology and source note

This report was assembled on August 24, 2026 using Patsnap MCP tools in sequence: disease_fetch, epidemiology_search, target_fetch, clinical_trial_search and drug_deal_search. Results reflect records returned on the access date and may change as databases update.

Ranking weights are 40% unmet need, 25% inverse competition and 35% market attractiveness. Inputs include disease-profile depth, epidemiology coverage, registered-trial activity, development-drug counts and direct recent transaction signals. Rerun searches with synonyms, disease roll-ups, target names and asset filters before a transaction or portfolio commitment.

Conclusion

The key question for Arteriovenous Malformations is whether a biologically grounded therapy can deliver material patient benefit in an identifiable population and remain differentiated through launch. The evidence assembled here supplies a structured starting point, while the explicit gaps define the next diligence plan.